Dermal Cell News 5.23 July 8, 2019 | |
| |
TOP STORYResearchers studied the role of RAC1P29S in melanoma development and revealed that RAC1P29S activated PAK, AKT, and a gene expression program initiated by the SRF/MRTF transcriptional pathway, which results in a melanocytic to mesenchymal phenotypic switch. [Cancer Cell] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONNoncoding dsRNA Induces Retinoic Acid Synthesis to Stimulate Hair Follicle Regeneration via TLR3 Scientists showed that self-noncoding dsRNA activated the anti-viral receptor toll like receptor 3 (TLR3) to induce intrinsic retinoic acid synthesis in a pattern that predicted new hair follicle formation after wounding in mice. [Nat Commun] Full Article Long-Term Expansion and Differentiation of Adult Murine Epidermal Stem Cells in 3D Organoid Cultures The authors describe an epidermal organoid culture system that allowed long-term, genetically stable expansion of adult epidermal stem cells. [Proc Natl Acad Sci USA] Abstract Scientists evaluated the paracrine effects of amniotic fluid-derived mesenchymal stem cell-conditioned medium overexpressing Nanog by monitoring secretory molecules related to hair regeneration and growth and proliferation of dermal papilla cells. [Exp Mol Med] Full Article Using keratinocytes derived from a patient with Kindler Syndrome, into which wild type kindlin‐1 has been expressed, scientists showed that kindlin‐1 bound to cyclin‐dependent kinase (CDK)1 and CDK2. [Exp Dermatol] Abstract SKIN CANCERS & DISORDERSm6A mRNA Demethylase FTO Regulates Melanoma Tumorigenicity and Response to Anti-PD-1 Blockade Investigators showed that N6-methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increased melanoma growth and decreased response to anti-PD-1 blockade immunotherapy. [Nat Commun] Full Article Elevated PTX3 production was observed in the population of MITFlow invasive cells but not in the population of MITFhigh differentiated melanoma cells. [Oncogene] Abstract To identify genes that are driven by signal transducer and activator of transcription 3 (STAT3) in human melanoma cells, scientists performed JAK/STAT signaling specific and global gene expression profiling of human melanoma cells with silenced STAT3 expression. [Lab Invest] Abstract Melanin Presence Inhibits Melanoma Cell Spread in Mice in a Unique Mechanical Fashion Researchers showed that melanin dramatically modified the elastic properties of melanoma cells and inhibited the cells invasive abilities in vitro. [Sci Rep] Full Article Subscribe to one of our other 19 science newsletters such as Extracellular Matrix News & Cancer Stem Cell News. | |
| |
REVIEWSCellular and Molecular Biology of Cancer Stem Cells in Melanoma: Possible Therapeutic Implications The authors highlight the molecular and biological features of the subpopulation of cancer stem cells, well known to be characterized by self-renewal properties, deeply involved in triggering the processes of tumor generation, metastasis, progression and drug resistance. [Semin Cancer Biol] Abstract Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
INDUSTRY NEWSIntensity Therapeutics Announces Clinical Collaboration with Merck Intensity Therapeutics, Inc. announced that it has entered into an agreement with Merck, through a subsidiary, to evaluate the combination of Intensity’s lead product candidate INT230-6 and KEYTRUDA®, Merck’s anti-programmed death receptor-1 therapy, in patients with advanced solid malignancies including pancreatic, bile duct, squamous cell and non-MSI high colon cancers. [Intensity Therapeutics, Inc.] Press Release Targovax ASA announced that clinical responses were observed in three out of nine patients in part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 checkpoint inhibitor refractory advanced melanoma, corresponding to an overall response rate of 33%. [Targovax ASA] Press Release The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dupixent® recommending extending its approval in the European Union to also include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. [Sanofi] Press Release Libtayo® (Cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union The European Commission has granted conditional marketing authorization for Libtayo® for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. [Sanofi] Press Release Almirall, S.A. and Dermira, Inc. announced that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis and certain other indications in Europe. [Almirall, S.A.] Press Release Cancer Vaccine to Treat Melanoma and Osteosarcoma Researchers at the University of Florida have developed a vaccine for melanoma and osteosarcoma cancers based on the tumor-specific antigen disialoganglioside. [University of Florida] Press Release | |
| |
POLICY NEWSHungarian Government Takes Control of Research Institutes despite Outcry After months of struggle between Hungary’s research ministry and its scientific community, the nation’s parliament ratified a law on 2 July that gives the government control over the 40 or so institutes belonging to the Hungarian Academy of Sciences. The government says that its aim is to make research more innovative. [Nature News] Editorial Stem Cell Funding Agency CIRM Is Nearly Out of Funds After funding stem cell research since 2004, the California Institute for Regenerative Medicine (CIRM) is running out of funds. The state agency currently has funding requests for $88 million pending but only $33 million left to give out to scientists. [The Scientist] Editorial Mexican President Eases Up on Researchers’ Travel Rules A month after announcing increased austerity measures on international travel for scientists, Mexico’s National Council of Science and Technology announced last month that at least one restriction would be loosened. Scientists would not require presidential approval for every trip abroad. [The Scientist] Editorial
| |
EVENTSNEW 2019 National Cancer Research Institute (NCRI) Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Faculty Position – Melanoma and Skin Immunobiology (Medical College of Wisconsin) NEW Doctoral Candidate – Tattoo Inks (Federal Institute for Risk Assessment) NEW Research Fellowship – Cancer Biology (Ninewells Hospital and Medical School) Postdoctoral Research Fellowships – Tissue Engineering (University of Oslo) Postdoctoral Fellowship – Cancer Immunology and Immunotherapy (H. Lee Moffitt Cancer Center) Postdoctoral Fellow – Cancer Drug Response Research (University of Texas at Austin) Research Lab Specialist – Tumor Microenvironment & Cell Behavior (University of Southern California) Postdoctoral Fellow or PhD Student – Cell and Developmental Biology (University of Geneva) Research Fellowship – Melanoma (Dana-Farber Cancer Institute) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|